Finanzas de Iambic Therapeutics, Inc. Common Stock (IAM)

$14.280

-0.483 (-3.38%)Al cierre

Comparativa sectorial de IAM

In the context of the broader market, IAM competes directly with industry leaders such as PRME and SANA. With a market capitalization of $700.58M, it holds a significant position in the sector. When comparing efficiency, IAM's gross margin of N/A stands against PRME's 100.00% and SANA's N/A. Such benchmarking helps identify whether Iambic Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Desempeño financiero de Iambic Therapeutics, Inc. Common Stock

The company shows no earnings with a P/E ratio of 0 and a forward P/E of 0, indicating it is not generating profits. Its price-to-sales ratio is quite high at 38.1, which raises concerns about valuation.

Financials

No data

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.